Literature DB >> 14704849

Retention of atherogenic lipoproteins in atherogenesis.

M Gustafsson1, C Flood, P Jirholt, J Borén.   

Abstract

Atherosclerosis is a multifactorial disease whose pathogenesis is still unclear. Mounting evidence, however, supports the concept that subendothelial retention of apoB100-containing lipoproteins is the initiating event in atherogenesis. Subsequently, a series of biological responses to this retained material leads to specific molecular and cellular processes that promote lesion formation.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14704849     DOI： 10.1007/s00018-003-3262-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN： 1420-682X            Impact factor:   9.261


  37 in total

1.  Primary percutaneous transluminal coronary angioplasty performed for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura.

Authors:  T Fuchi; T Kondo; K Sase; M Takahashi
Journal:  Jpn Circ J       Date:  1999-02

2.  Coronary artery bypass in two patients with immune thrombocytopenic purpura without preoperative splenectomy.

Authors:  S J Jubelirer
Journal:  W V Med J       Date:  1992-11

3.  [A case of CABG in a patient with chronic idiopathic thrombocytopenic purpura].

Authors:  Y Terada; T Ino; Y Wanibuchi; H Takagi; Y Shimoyama; S Furuta
Journal:  Nihon Kyobu Geka Gakkai Zasshi       Date:  1990-01

4.  Thrombocytopenia, immunoglobulin treatment, and acute myocardial infarction--a case report.

Authors:  Guy Amit; Tikva Yermiyahu; Harel Gilutz; Reuben Ilia; Doron Zahger
Journal:  Angiology       Date:  2005 Mar-Apr       Impact factor: 3.619

5.  Coronary revascularization in a patient with immune thrombocytopenic purpura.

Authors:  Man-Cai Fong; Kuan-Chun Chen; Hsin-Bang Leu; Lung-Ching Chen
Journal:  J Chin Med Assoc       Date:  2006-09       Impact factor: 2.743

6.  [Percutaneous transluminal coronary angioplasty in a patient with idiopathic thrombocytopenic purpura].

Authors:  Luis Gustavo M Marques; Murillo Kenji Furukawa; Thenyson Pereira Leitão; José Luis A Quiñones; Fernando César de Queiroz; Rogerio Felippe Tiossi; Virgílio Ribeiro Franco; Carlos Eduardo M Domingues; Decio Salvadori
Journal:  Arq Bras Cardiol       Date:  2005-05-02       Impact factor: 2.000

7.  [Minimally invasive direct coronary artery bypass in a patient with idiopathic thrombocytopenic purpura; report of a reoperative case].

Authors:  H Gotoh; Y Fukaya; T Kohno; J Amano
Journal:  Kyobu Geka       Date:  2002-11

8.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).

Authors:  Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs
Journal:  Circulation       Date:  2004-08-03       Impact factor: 29.690

9.  Combined coronary revascularization and splenectomy.

Authors:  R Koike; H Suma; T Oku; H Satoh; Y Sawada; A Takeuchi
Journal:  Ann Thorac Surg       Date:  1989-12       Impact factor: 4.330

10.  Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura.

Authors:  George A Stouffer; Jana Hirmerova; Stephan Moll; Bryon Rubery; Mark Napoli; E Magnus Ohman; Ross Simpson
Journal:  Catheter Cardiovasc Interv       Date:  2004-03       Impact factor: 2.692
View more
  5 in total

1.  Implication of vitamin A deficiency on vascular injury related to inflammation and oxidative stress. Effects on the ultrastructure of rat aorta.

Authors:  Laura V Gatica; Liliana B Oliveros; Matías F Pérez Díaz; Nora S Domínguez; Miguel W Fornes; María S Gimenez
Journal:  Eur J Nutr       Date:  2011-04-22       Impact factor: 5.614

2.  Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression.

Authors:  Cecilia M Devlin; Andrew R Leventhal; George Kuriakose; Edward H Schuchman; Kevin Jon Williams; Ira Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-31       Impact factor: 8.311

Review 3.  Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.

Authors:  Marja-Riitta Taskinen; Chris J Packard; Jan Borén
Journal:  Curr Atheroscler Rep       Date:  2019-05-20       Impact factor: 5.113

Review 4.  Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

Authors:  Marja-Riitta Taskinen; Jan Borén
Journal:  Curr Atheroscler Rep       Date:  2016-10       Impact factor: 5.113

Review 5.  The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.

Authors:  Jan Borén; Chris J Packard; Marja-Riitta Taskinen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-28       Impact factor: 5.555
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.